• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.

作者信息

Takano Masashi, Goto Tomoko, Kato Masafumi, Sasaki Naoki, Miyamoto Morikazu, Furuya Kenichi

出版信息

Int J Clin Oncol. 2013 Jun;18(3):556-7. doi: 10.1007/s10147-012-0404-x. Epub 2012 May 3.

DOI:10.1007/s10147-012-0404-x
PMID:22552358
Abstract
摘要

相似文献

1
Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.即使在复发性或难治性卵巢透明细胞癌中对使用传统细胞毒性药物进行化疗有反应的患者中，反应持续时间也较短。
Int J Clin Oncol. 2013 Jun;18(3):556-7. doi: 10.1007/s10147-012-0404-x. Epub 2012 May 3.
2
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.复发性或持续性卵巢透明细胞癌的挽救性化疗：单中心 20 例患者系列研究。
Int J Clin Oncol. 2013 Feb;18(1):148-53. doi: 10.1007/s10147-011-0357-5. Epub 2011 Dec 10.
3
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).一项使用多西他赛和伊立替康进行联合化疗治疗 TC 难治性或 TC 耐药性卵巢癌（GOGO-OV2 研究）和原发性透明细胞或黏液性卵巢癌（GOGO-OV3 研究）的 II 期研究。
Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):259-63. doi: 10.1016/j.ejogrb.2013.06.035. Epub 2013 Jul 20.
4
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.伊立替康用于转移性上皮性卵巢癌或腹膜癌患者的II期试验。
J Clin Oncol. 2003 Jan 15;21(2):291-7. doi: 10.1200/JCO.2003.02.091.
5
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.老年女性腹腔内化疗的疗效及毒性评估
Gynecol Oncol. 2017 Aug;146(2):268-272. doi: 10.1016/j.ygyno.2017.05.032. Epub 2017 Jun 2.
6
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.复发性卵巢透明细胞癌缺乏有效的全身治疗方法。
Gynecol Oncol. 2007 May;105(2):404-8. doi: 10.1016/j.ygyno.2006.12.024. Epub 2007 Feb 9.
7
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.Ⅰ期卵巢透明细胞癌的辅助化疗：全面分期患者的分析。
Int J Gynecol Cancer. 2012 May;22(4):573-8. doi: 10.1097/IGC.0b013e31823fd413.
8
Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.与单药卡铂相比，卡铂与紫杉烷联合辅助化疗用于早期上皮性卵巢癌的疗效比较。
Oncol Rep. 2007 Nov;18(5):1249-56.
9
Irinotecan in epithelial ovarian cancer.伊立替康用于上皮性卵巢癌
Oncology (Williston Park). 2002 May;16(5 Suppl 5):29-31.
10
Use of IP chemotherapy in ovarian cancer: the critical questions.IP化疗在卵巢癌中的应用：关键问题
Oncology (Williston Park). 2011 Feb;25(2):170, 173-4.

引用本文的文献

1
Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma.子宫内膜异位症作为卵巢透明细胞癌进展后生存预后因素的作用。
Mol Clin Oncol. 2017 Dec;7(6):1027-1031. doi: 10.3892/mco.2017.1468. Epub 2017 Oct 23.
2
Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.磷脂酰肌醇蛋白聚糖-3衍生肽疫苗疗法对难治性卵巢透明细胞癌患者生存的疗效。
Oncoimmunology. 2016 Sep 30;5(11):e1238542. doi: 10.1080/2162402X.2016.1238542. eCollection 2016.
3
The role of immune checkpoint inhibition in the treatment of ovarian cancer.

本文引用的文献

1
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.复发性或持续性卵巢透明细胞癌的挽救性化疗：单中心 20 例患者系列研究。
Int J Clin Oncol. 2013 Feb;18(1):148-53. doi: 10.1007/s10147-011-0357-5. Epub 2011 Dec 10.
2
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.探讨晚期或复发性卵巢透明细胞癌女性的姑息治疗结局。
Gynecol Oncol. 2011 Jul;122(1):107-10. doi: 10.1016/j.ygyno.2011.03.011. Epub 2011 Apr 3.
3
Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.
免疫检查点抑制在卵巢癌治疗中的作用。
Gynecol Oncol Res Pract. 2016 Nov 24;3:11. doi: 10.1186/s40661-016-0033-6. eCollection 2016.
4
X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.X 染色体连锁凋亡抑制剂作为卵巢透明细胞癌化疗耐药的关键因素。
Br J Cancer. 2014 Jun 10;110(12):2881-6. doi: 10.1038/bjc.2014.255. Epub 2014 May 22.
5
Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.进展性复发性卵巢透明细胞癌对磷脂酰肌醇蛋白聚糖-3衍生肽疫苗治疗有显著临床反应：两例病例报告
Hum Vaccin Immunother. 2014;10(2):338-43. doi: 10.4161/hv.27217. Epub 2013 Nov 21.
每周给予替西罗莫司治疗经大量预处理的卵巢透明细胞癌患者：六例报告。
Int J Clin Oncol. 2011 Oct;16(5):605-9. doi: 10.1007/s10147-010-0177-z. Epub 2011 Jan 18.
4
Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.复发性或难治性卵巢透明细胞癌二线化疗的低反应率：一项日本透明细胞癌回顾性研究
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):937-42. doi: 10.1111/j.1525-1438.2007.01158.x. Epub 2007 Dec 13.
5
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.一例耐药性透明细胞卵巢癌患者，首次使用吉西他滨时及再次使用时均显示出反应。
Cancer Chemother Pharmacol. 2007 Aug;60(3):459-61. doi: 10.1007/s00280-007-0479-7. Epub 2007 Apr 11.
6
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.复发性卵巢透明细胞癌缺乏有效的全身治疗方法。
Gynecol Oncol. 2007 May;105(2):404-8. doi: 10.1016/j.ygyno.2006.12.024. Epub 2007 Feb 9.
7
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.紫杉醇联合铂类化疗用于晚期或复发性卵巢透明细胞腺癌：一项多中心试验。
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6. doi: 10.1111/j.1525-1438.2006.00289.x.
8
Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.一名晚期卵巢透明细胞癌患者对盐酸伊立替康和奈达铂完全缓解。
Int J Clin Oncol. 2004 Oct;9(5):403-5. doi: 10.1007/s10147-004-0413-5.
9
Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.一名化疗耐药的卵巢透明细胞腺癌患者对放射治疗的完全缓解。
Arch Gynecol Obstet. 2002 Dec;267(2):98-100. doi: 10.1007/s00404-001-0258-3.
10
Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer.大剂量醋酸甲地孕酮治疗铂类难治性上皮性卵巢癌的II期研究
Anticancer Drugs. 2001 Oct;12(9):719-24. doi: 10.1097/00001813-200110000-00002.